Why InterVene’s first 30 Recana cases could reshape treatment for venous in-stent restenosis
InterVene has completed 30 Recana cases, raising new questions about venous ISR treatment, adoption, and launch strategy. Read the full analysis.
What Boston Scientific’s $14.5bn Penumbra buyout means for stroke and clot intervention markets
Boston Scientific Corporation has announced a definitive agreement to acquire Penumbra, Inc. for approximately $14.5 billion, marking one of its largest acquisitions to date in the medical device sector. The deal, structured as approximately 73 percent cash and 27 percent stock, offers Penumbra shareholders $374 per share and is expected to close in 2026, subject […]